Did an iceberg just wallop into Acorda (ACOR) stock? The drug maker’s shares are plunging at breakneck speed of almost 22% after the U.
J.P.
Can These Biotech Stocks Recover from an FDA Setback and a Stark 2Q Preliminary Earnings Stumble?
Acorda Therapeutics Inc (NASDAQ:ACOR) stock got hammered 26% Tuesday morning as Wall Street came down hard on the company. The reason?
Yesterday afternoon, Acorda Therapeutics Inc (NASDAQ:ACOR) presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically …
Acorda Therapeutics Inc (NASDAQ:ACOR) shares climbed nearly 10% to $16.80 in after-hours trading Monday, after the drug maker announced that its Parkinson’s disease drug, …
On Friday, Acorda Therapeutics Inc (NASDAQ:ACOR) was met with misfortune after a district judge invalidated four patents for its multiple sclerosis drug Ampyra, …
Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) shares skyrocketed over 40% in Friday’s trading session, after the company announced that the FDA has designated as …
Acorda Therapeutics Inc (NASDAQ:ACOR) shares rose 13% in Thursday’s trading session, after the drug maker announced topline data for CVT-301, an inhaled levodopa therapy …
Acorda Therapeutics Inc (NASDAQ:ACOR) investors are having a rough morning, after the drug maker announced that it plans to discontinue the development of Ampyra …
